Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment initiation rates of patients with positive anti-hepatitis C virus results in tertiary hospitals in Turkey.
Çelen MK, Ertürk Şengel B, Kaya Ş, Demirtürk N, Azap A, Pullukçu H, Eroğlu E, Yıldırım F, Barut HŞ, Zerdali E, Sağmak Tartar A, Mete AÖ, Şahin AM, Mutay Suntur B, Sarı ND, Yılmaz E, Candevir A, Şimşek F, İnan D, Akhan S, Asan A, Günal Ö, Ural O, Parlak M, Çabalak M, Nazik S, Hızel K, Kınıklı S, Beştepe Dursun Z, Batırel A, Mermutluoğlu Ç. Çelen MK, et al. J Infect Dev Ctries. 2024 Mar 31;18(3):441-449. doi: 10.3855/jidc.17910. J Infect Dev Ctries. 2024. PMID: 38635621 Free article.
Evaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic?
Arslan E, Yildiz Y, Karaşahin Ö, Demir Y, Tümbül Mermutluoğlu Ç, Ünlü G, Kuşçu F, Kaya Ş, Akgül F, Damar Çakirca T, Yilmaz Karadağ F, Altunişik Toplu S, Nazik S, Akdemir İ, Özer Balin Ş, Kandemir FÖ, İnan D, Bayindir Y, Taşova Y, Çelen MK. Arslan E, et al. Among authors: celen mk. Eur J Gastroenterol Hepatol. 2024 Apr 1;36(4):438-444. doi: 10.1097/MEG.0000000000002722. Epub 2024 Feb 23. Eur J Gastroenterol Hepatol. 2024. PMID: 38407855
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T; CERTAIN-1 Study Team. Wagenlehner FM, et al. N Engl J Med. 2024 Feb 15;390(7):611-622. doi: 10.1056/NEJMoa2304748. N Engl J Med. 2024. PMID: 38354140 Clinical Trial.
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Anastasiou OE, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Heidrich B, Mederacke I, von der Leyen H, Kahlhöfer J, von Karpowitz M, Hardtke S, Cornberg M, Yurdaydin C, Wedemeyer H. Anastasiou OE, et al. Among authors: celen mk. Liver Int. 2024 Jan;44(1):139-147. doi: 10.1111/liv.15745. Epub 2023 Oct 3. Liver Int. 2024. PMID: 37787009
Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, Chuang WL, Janssen HLA, Fung S, Izumi N, Abdurakhmanov D, Jabłkowski M, Celen MK, Ma X, Caruntu F, Flaherty JF, Abramov F, Wang H, Camus G, Osinusi A, Pan CQ, Shalimar D, Seto WK, Gane E. Chan HLY, et al. Among authors: celen mk. Am J Gastroenterol. 2023 Aug 10;119(3):486-96. doi: 10.14309/ajg.0000000000002468. Online ahead of print. Am J Gastroenterol. 2023. PMID: 37561058 Free PMC article.
First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort.
Karasahin O, Kalkan IA, Dal T, Toplu SA, Harputluoglu M, Mete AO, Komur S, Sarigul F, Yildiz Y, Esmer F, Kandemir O, Nazik S, Inan D, Akgul F, Kaya S, Tunc N, Bayindir Y, Balin SO, Tasova Y, Aktar F, Oner MM, Ayhan M, Demir Y, Celen MK. Karasahin O, et al. Among authors: celen mk. Hepatol Forum. 2023 May 18;4(2):61-68. doi: 10.14744/hf.2022.2022.0043. eCollection 2023 Mar. Hepatol Forum. 2023. PMID: 37250926 Free PMC article.
Comparison of Immunological and Virological Recovery with Rapid, Early, and Late Start of Antiretroviral Treatment in Naive Plwh: Real-World Data.
Sarıgül Yıldırım F, Candevir A, Akhan S, Kaya S, Çabalak M, Ersöz G, İnan D, Ceren N, Karaoğlan İ, Damar Çakırca T, Özer Balin Ş, Alkan S, Kandemir Ö, Üser Ü, Karabay O, Çelen MK. Sarıgül Yıldırım F, et al. Among authors: celen mk. Int J Gen Med. 2023 May 17;16:1867-1877. doi: 10.2147/IJGM.S393370. eCollection 2023. Int J Gen Med. 2023. PMID: 37213471 Free PMC article.
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K, Kahlhöfer J, Dörge P, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, Wedemeyer H, Deterding K; HIDIT-2 Study Team. Dinkelborg K, et al. Among authors: celen mk. Liver Int. 2023 Aug;43(8):1663-1676. doi: 10.1111/liv.15602. Epub 2023 May 15. Liver Int. 2023. PMID: 37183524 Clinical Trial.
69 results